Announcing Calidi’s Stock Split
Calidi Biotherapeutics has authorized a one-for-ten reverse stock split, effective July 15, 2024. The split will be applied to...
Acticor Biotech: Disclosure of Voting Rights, Shares May 2024
ACTICOR BIOTECH, a clinical-stage pharmaceutical company, reports its voting rights and shares as of May 31, 2024. The company...
How Sanofi Incorporates Patient Data in Clinical Trials
At the recent Clinical Trial Outsourcing East Coast conference, Rachel Nering, Global Head of Early Development Clinical Operations at...
Merck and Orion Exclusive Rights to Opevesostat for Metastatic Prostate Cancer
Merck and Orion Corporation have converted their co-development and co-commercialization agreement for opevesostat into an exclusive global license for...
How N-Power Medicine’s Series B Funding Will Revolutionize Oncology Trial Access
N-Power Medicine has secured initial funding in a Series B round, boosting its total funding to $72 million. Led...
TAURx Submits Extraordinary Application for HMTM as Alzheimer’s Disease Breakthrough
TauRx Pharmaceuticals has submitted a Marketing Authorisation Application (MAA) in the UK for hydromethylthionine mesylate (HMTM), a potential treatment...
Mendel’s AI System Outperforms GPT-4 in Patient Cohort Identification
Mendel, a leader in clinical AI, has announced advancements in its neuro-Symbolic AI system, which automates the identification of...
AI-Assisted Trials: Hidden Secrets to Help Study Coordinators
Integrating AI is a game-changer in the ever-evolving landscape of clinical trials, and it is now being applied to...
Follow The Money: Eye-Opening Trends in Clinical Trial Investment
The clinical trial industry is experiencing a significant shift in investment capital, with a current focus on innovative technology...
Breakthrough Med: Epcoritamab Revolutionizes Follicular Lymphoma Treatment
The European Medicines Agency (EMA) has recommended granting marketing authorization for epcoritamab, a monoclonal antibody for treating relapsed or...